Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.07 -1.23 (-7.11%)

Official Closing Price Updated: 4:10 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

Today 6:45 EDT

From Bausch + Lomb Corporation

Via Business Wire

3 Low-Volatility Stocks with Open Questions

October 08, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

Via StockStory

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

October 06, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

October 05, 2026

From Bausch + Lomb Corporation

Via Business Wire

3 Small-Cap Stocks That Concern Us

September 17, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Via StockStory

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

September 11, 2026

From Bausch + Lomb Corporation

Via Business Wire

1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

September 09, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

September 02, 2026

From Bausch + Lomb Corporation

Via Business Wire

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

September 01, 2026

From Bausch + Lomb Corporation

Via Business Wire

August 28, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

3 Healthcare Stocks We Steer Clear Of

August 27, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Via StockStory

Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential ↗

August 25, 2026

Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.

Via Benzinga

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack

August 24, 2026

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty...

Via StockStory

Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal ↗

August 24, 2026

Bausch + Lomb (NYSE:BLCO) said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at...

Via MarketBeat

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

August 24, 2026

From Bausch + Lomb Corporation

Via Business Wire

3 Stocks Under $50 We’re Skeptical Of

August 18, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Via StockStory

Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000 ↗

August 13, 2026

Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months.

Via The Motley Fool

Topics Regulatory Compliance

Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Revenue grew 8% while EBITDA surged 28%, driven by dry eye and surgical strength.

Via The Motley Fool

Topics Earnings

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

August 06, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Q2 Earnings Call Highlights ↗

July 29, 2026

Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook....

Via MarketBeat

Topics Earnings

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations

July 29, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $1.39 bil...

Via StockStory

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

July 29, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

July 27, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what to expect. Bausch + Lomb beat analysts’ ...

Via StockStory

Topics Artificial Intelligence

3 Reasons to Avoid BLCO and 1 Stock to Buy Instead

July 22, 2026

Over the past six months, Bausch + Lomb’s stock price fell to $15.99. Shareholders have lost 7% of their capital, which is disappointing considering the S&P ...

Via StockStory

Topics Stocks

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

July 16, 2026

From Bausch + Lomb Corporation

Via Business Wire

Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today

July 10, 2026

What Happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its experimental glaucoma t...

Via StockStory

Topics Artificial Intelligence Economy Initial Public Offering

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

July 09, 2026

From Bausch + Lomb

Via Business Wire

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

July 09, 2026

From Bausch + Lomb

Via Business Wire

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

July 06, 2026

From Bausch + Lomb Corporation

Via Business Wire

July 06, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.